COMBINATION THERAPIES FOR TREATING HER2-POSITIVE CANCERS THAT ARE RESISTANT TO HER2-TARGETED THERAPIES

摘要

Methods for treating cancer patients (e.g., cancer patients resistant or intolerant to pertuzumab and ado-trastuzumab emtansine) having HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of a doxorubicin-loaded immunoliposome with a targeting moiety that is an anti-HER2 antibody that is not an inhibitor of HER2 signaling and an anti-cancer therapeutic comprising a doxorubicin-free anti-cancer therapeutic comprising a different anti-HER2 antibody.

主权项

1. A method of follow-on treatment of a HER2-positive tumor in a human patient comprising administering to the patient a therapeutically effective amount of an immunoliposome comprising encapsulated doxorubicin and a HER2-binding antibody, in combination with an anti-HER2 therapeutic that comprises trastuzumab or another anti-HER2 antibody, wherein, prior to the follow-on treatment, the patient had received treatment with one or more of 1) trastuzumab, 2) pertuzumab, and 3) ado-trastuzumab emtansine, and had experienced tumor progression following such prior treatment initiation with, or was intolerant to treatment with pertuzumab and had experienced tumor progression following such prior treatment initiation with, or was intolerant to such prior treatment with ado-trastuzumab emtansine.